文献速递肿瘤 PET/CT核素与放射性配体治疗

基于全面、病灶级、纵向[68Ga]Ga-DOTA-TATE PET衍生特征的模型对接受[177Lu]Lu-DOTA-TATE治疗的神经内分泌肿瘤患者预后预测更优

Models using comprehensive, lesion-level, longitudinal [68Ga]Ga-DOTA-TATE PET-derived features lead to superior outcome prediction in neuroendocrine tumor patients treated with [177Lu]Lu-DOTA-TATE.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-05-25

这项回顾性研究纳入36例接受[177Lu]Lu-DOTA-TATE治疗的神经内分泌肿瘤患者,在基线和治疗后行[68Ga]Ga-DOTA-TATE PET显像,对所有病灶进行分割、解剖标注和纵向匹配,测量病灶级摄取及其变化,构建并选择患者级特征以建模无进展生存期。多变量线性回归模型的一致性指数为0.826,AUC为0.88(特异性0.85,敏感性0.81),生存分析实现显著患者分层(p<.001),风险比为3⨯10-5,且该建模方法优于所有单特征预测模型。

要点

  • 全面、病灶级、纵向68GA-SSTR-PET特征结合多变量线性回归模型对PRRT结局预测优秀。
  • 模型一致性指数0.826,AUC 0.88(特异性0.85,敏感性0.81),生存分层p<.001。
  • 多变量线性回归建模方法优于所有单特征预测模型。

核心结论

  • 全面、病灶级、纵向68GA-SSTR-PET分析结合多变量线性回归建模对NET患者PRRT结局预测优秀,优于非全面、患者级和单时间点特征预测。

研究设计与样本

  • 回顾性研究纳入36例接受[177Lu]Lu-DOTA-TATE治疗并在基线和治疗后行[68Ga]Ga-DOTA-TATE显像的NET患者。
  • 对所有病灶进行分割、解剖标注和纵向匹配,测量病灶级摄取及摄取变化。
  • 构建并选择患者级特征用于无进展生存期建模,通过一致性指数、ROC分析和生存分析验证模型。

主要发现

  • 36例NET患者被分层为差缓解者和好缓解者(PFS≥25个月)。
  • 选择4个患者级特征,多变量线性回归一致性指数为0.826,AUC为0.88(特异性0.85,敏感性0.81)。
  • 生存分析实现显著患者分层(p<.001),风险比为3⨯10-5。
  • 基准研究中多变量线性回归建模方法优于所有单特征预测模型。

关键数值与推荐

  • 好缓解者定义为PFS≥25个月。
  • 多变量线性回归模型一致性指数0.826,AUC 0.88(特异性0.85,敏感性0.81)。
  • 生存分析分层p<.001,风险比3⨯10-5。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Somatostatin receptor (SSTR) imaging features are predictive of treatment outcome for neuroendocrine tumor (NET) patients receiving peptide receptor radionuclide therapy (PRRT). However, comprehensive (all metastatic lesions), longitudinal (temporal variation), and lesion-level measured features have never been explored. Such features allow for capturing the heterogeneity in disease response to treatment. Furthermore, models combining these features are lacking. In this work we evaluated the predictive power of comprehensive, longitudinal, lesion-level 68GA-SSTR-PET features combined with a multivariate linear regression (MLR) model. METHODS: This retrospective study enrolled NET patients treated with [177Lu]Lu-DOTA-TATE and imaged with [68Ga]Ga-DOTA-TATE at baseline and post-therapy. All lesions were segmented, anatomically labeled, and longitudinally matched. Lesion-level uptake and variation in uptake were measured. Patient-level features were engineered and selected for modeling of progression-free survival (PFS). The model was validated via concordance index, patient classification (ROC analysis), and survival analysis (Kaplan-Meier and Cox proportional hazards). The MLR was benchmarked against single feature predictions. RESULTS: Thirty-six NET patients were enrolled and stratified into poor and good responders (PFS ≥ 25 months). Four patient-level features were selected, the MLR concordance index was 0.826, and the AUC was 0.88 (0.85 specificity, 0.81 sensitivity). Survival analysis led to significant patient stratification (p<.001) and hazard ratio (3⨯10-5). Lastly, in a benchmark study, the MLR modeling approach outperformed all the single feature predictors. CONCLUSION: Comprehensive, lesion-level, longitudinal 68GA-SSTR-PET analysis, combined with MLR modeling, leads to excellent predictions of PRRT outcome in NET patients, outperforming non-comprehensive, patient-level, and single time-point feature predictions. MESSAGE: Neuroendocrine tumor, peptide receptor radionuclide therapy, Somatostatin Receptor Imaging, Outcome Prediction, Treatment Response Assessment.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Santoro-Fernandes V, Schott B, Deatsch A, et al. Models using comprehensive, lesion-level, longitudinal [68Ga]Ga-DOTA-TATE PET-derived features lead to superior outcome prediction in neuroendocrine tumor patients treated with [177Lu]Lu-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2024. PMID: 38795121. doi:10.1007/s00259-024-06767-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。